Co-Diagnostics, Inc. (CODX): Results of Operations and Financial Condition
Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovatio
How this was made
The 30-second read
Why it matters
Key actionable items for traders are the disclosed $3.0M private placement, the FDA 510(k) submission plus concurrent CLIA waiver by application for the Flu A/B & RSV multiplex test, and ongoing cash burn reflected in operating and net losses.
Market read
This is a primary disclosure combining quarterly financials with specific regulatory and financing milestones, which can move a small-cap diagnostics name even without clearance yet.
What to watch
Cash is only $3.6M at June 30, 2026; traders may focus on burn rate versus the $3.0M placement size and whether additional financing is needed before commercialization milestones.
Background
The 8-K (Item 2.02) includes Co-Diagnostics’ Q2 2026 financial results and a press-release style update on regulatory, clinical, and commercialization progress.
Ticker impact
Co-Diagnostics reported Q2 results and disclosed a $3.0M private placement plus a submitted FDA 510(k) for its Flu A/B & RSV test on the Co-Dx PCR Pro instrument.
Moderate upside bias on risk-on sentiment, but likely capped by small revenue base and ongoing net losses.
The filing is a primary disclosure (8-K with results and financing) and includes specific regulatory milestones, but it does not provide FDA clearance timing or revenue inflection.
Market effects
Adds incremental evidence of continued commercialization efforts in molecular diagnostics, with emphasis on point-of-care multiplex testing and platform integration.
Highlights MENA manufacturing localization (Saudi) and Latin America distribution (Mexico), which may influence regional partner expectations.
Continues global health diagnostics development (TB and Ebola assay strategy), relevant to international funding and partnership narratives.
Counterpoint
The FDA 510(k) submission is not clearance, and the company still reported a sizable operating loss with very low revenue, so the market may treat this as incremental rather than transformative.
Key entities
- companyCo-Diagnostics, Inc.
Molecular diagnostics company reporting Q2 2026 results, regulatory submissions, and a $3.0M private placement.
- product_platformCo-Dx PCR Pro instrument
Instrument platform for which the company submitted a 510(k) for the Flu A/B & RSV upper respiratory multiplex test.
- regulatorU.S. Food and Drug Administration (FDA)
Agency to which the company submitted a 510(k) and CLIA waiver by application for the multiplex test.
